IBDEI0BO ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5282,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5282,1,3,0)
 ;;=3^Rapidly progr neph synd w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,5282,1,4,0)
 ;;=4^N01.1
 ;;^UTILITY(U,$J,358.3,5282,2)
 ;;=^5015502
 ;;^UTILITY(U,$J,358.3,5283,0)
 ;;=N01.2^^27^344^67
 ;;^UTILITY(U,$J,358.3,5283,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5283,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,5283,1,4,0)
 ;;=4^N01.2
 ;;^UTILITY(U,$J,358.3,5283,2)
 ;;=^5015503
 ;;^UTILITY(U,$J,358.3,5284,0)
 ;;=N01.3^^27^344^65
 ;;^UTILITY(U,$J,358.3,5284,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5284,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,5284,1,4,0)
 ;;=4^N01.3
 ;;^UTILITY(U,$J,358.3,5284,2)
 ;;=^5015504
 ;;^UTILITY(U,$J,358.3,5285,0)
 ;;=N01.4^^27^344^64
 ;;^UTILITY(U,$J,358.3,5285,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5285,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,5285,1,4,0)
 ;;=4^N01.4
 ;;^UTILITY(U,$J,358.3,5285,2)
 ;;=^5015505
 ;;^UTILITY(U,$J,358.3,5286,0)
 ;;=N01.5^^27^344^68
 ;;^UTILITY(U,$J,358.3,5286,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5286,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,5286,1,4,0)
 ;;=4^N01.5
 ;;^UTILITY(U,$J,358.3,5286,2)
 ;;=^5015506
 ;;^UTILITY(U,$J,358.3,5287,0)
 ;;=N01.6^^27^344^63
 ;;^UTILITY(U,$J,358.3,5287,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5287,1,3,0)
 ;;=3^Rapidly progr neph synd w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,5287,1,4,0)
 ;;=4^N01.6
 ;;^UTILITY(U,$J,358.3,5287,2)
 ;;=^5015507
 ;;^UTILITY(U,$J,358.3,5288,0)
 ;;=N01.7^^27^344^66
 ;;^UTILITY(U,$J,358.3,5288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5288,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,5288,1,4,0)
 ;;=4^N01.7
 ;;^UTILITY(U,$J,358.3,5288,2)
 ;;=^5015508
 ;;^UTILITY(U,$J,358.3,5289,0)
 ;;=N01.8^^27^344^71
 ;;^UTILITY(U,$J,358.3,5289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5289,1,3,0)
 ;;=3^Rapidly progr neph synd w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,5289,1,4,0)
 ;;=4^N01.8
 ;;^UTILITY(U,$J,358.3,5289,2)
 ;;=^5015509
 ;;^UTILITY(U,$J,358.3,5290,0)
 ;;=N01.9^^27^344^72
 ;;^UTILITY(U,$J,358.3,5290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5290,1,3,0)
 ;;=3^Rapidly progr neph synd w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,5290,1,4,0)
 ;;=4^N01.9
 ;;^UTILITY(U,$J,358.3,5290,2)
 ;;=^5015510
 ;;^UTILITY(U,$J,358.3,5291,0)
 ;;=N02.0^^27^344^80
 ;;^UTILITY(U,$J,358.3,5291,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5291,1,3,0)
 ;;=3^Recurrent & perst hematur w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,5291,1,4,0)
 ;;=4^N02.0
 ;;^UTILITY(U,$J,358.3,5291,2)
 ;;=^5015511
 ;;^UTILITY(U,$J,358.3,5292,0)
 ;;=N02.1^^27^344^79
 ;;^UTILITY(U,$J,358.3,5292,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5292,1,3,0)
 ;;=3^Recurrent & perst hematur w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,5292,1,4,0)
 ;;=4^N02.1
 ;;^UTILITY(U,$J,358.3,5292,2)
 ;;=^5015512
 ;;^UTILITY(U,$J,358.3,5293,0)
 ;;=N02.2^^27^344^77
 ;;^UTILITY(U,$J,358.3,5293,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5293,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,5293,1,4,0)
 ;;=4^N02.2
 ;;^UTILITY(U,$J,358.3,5293,2)
 ;;=^5015513
 ;;^UTILITY(U,$J,358.3,5294,0)
 ;;=N02.3^^27^344^74
 ;;^UTILITY(U,$J,358.3,5294,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,5294,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
